Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT02538926 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2018-11-14
Summary
This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride with asparaginase work in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Asparaginase breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. Giving combination chemotherapy with asparaginase may work better in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
Conditions
- B Acute Lymphoblastic Leukemia
- B Lymphoblastic Lymphoma
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent B Lymphoblastic Lymphoma
- Recurrent T Lymphoblastic Leukemia/Lymphoma
- Refractory B Lymphoblastic Lymphoma
- Refractory T Lymphoblastic Lymphoma
- T Acute Lymphoblastic Leukemia
- T Lymphoblastic Lymphoma
Interventions
- DRUG
-
Asparaginase
Given IM or IV
- DRUG
-
Given IV
- DRUG
-
Doxorubicin Hydrochloride
Given IV
- DRUG
-
Etoposide
Given IV
- DRUG
-
Imatinib Mesylate
Given PO
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
- DRUG
-
Given PO
- BIOLOGICAL
-
Given IV
- DRUG
-
Vincristine Sulfate
Given IV
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH - lead OTHER
Principal Investigators
-
Ryan Cassaday · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-01
- Primary Completion
- 2020-07-30
- Completion
- 2021-07-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
NCT00003388 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
NCT02213913 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT06210750 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
NCT00074282 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00001337 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
NCT04139304 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
NCT00059839 ·Status: COMPLETED ·Phase: PHASE3
-
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
NCT03925428 ·Status: WITHDRAWN ·Phase: PHASE1
-
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
NCT01445535 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02199184 ·Status: COMPLETED ·Phase: PHASE2
-
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03518112 ·Status: TERMINATED ·Phase: PHASE2
-
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
NCT00882206 ·Status: TERMINATED ·Phase: PHASE2
-
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT01769209 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
NCT02561273 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00032019 ·Status: COMPLETED ·Phase: PHASE2
-
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
NCT01887587 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
NCT02481310 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
NCT02293109 ·Status: COMPLETED ·Phase: PHASE1
-
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00062296 ·Status: COMPLETED ·Phase: PHASE2
-
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
NCT07097363 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
NCT02911142 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma
NCT00004162 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00005977 ·Status: COMPLETED ·Phase: PHASE3
-
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
NCT00005786 ·Status: TERMINATED ·Phase: NA